3B

3billion Inc.

AI-powered genome sequencing and reanalysis to diagnose rare diseases globally.

394800 | KO

Overview

Corporate Details

ISIN(s):
KR7394800007
LEI:
Country:
South Korea
Address:
서울특별시 강남구 테헤란로 415 8층(삼성동, 엘7호텔스강남타워), 강남구
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

3billion Inc. is a biotechnology company specializing in AI-driven genetic diagnostics for rare diseases. The company aims to end the "diagnostic odyssey" for patients by providing fast, accurate, and comprehensive testing solutions. Leveraging its artificial intelligence platform, 3billion analyzes over 20,000 genes through services like whole-exome (3B-EXOME) and whole-genome sequencing. A key differentiator is its commitment to unlimited reanalysis, which re-evaluates patient data against new scientific discoveries to increase diagnostic yield over time. 3billion collaborates with a global network of over 700 institutions and 1,600 healthcare providers across more than 70 countries to make its one-stop diagnostic services accessible to patients with suspected rare diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-09 00:00
M&A Activity
타법인주식및출자증권취득결정
Korean 26.0 KB
2025-09-01 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-08-29 00:00
Pre-Annual General Meeting Information
주주총회소집결의 (임시주주총회)
Korean 9.8 KB
2025-08-29 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.5 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 875.0 KB
2025-07-02 00:00
Regulatory News Service
단일판매ㆍ공급계약체결
Korean 9.8 KB
2025-07-02 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 69.7 KB
2025-06-09 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 647.6 KB
2025-04-17 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.2 MB
2025-04-16 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.5 KB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 21.5 KB
2025-03-31 00:00
Remuneration Information
주식매수선택권부여에관한신고
Korean 14.6 KB
2025-03-21 00:00
Audit Report / Information
감사보고서제출
Korean 19.1 KB
2025-03-21 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 367.7 KB

Automate Your Workflow. Get a real-time feed of all 3billion Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for 3billion Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for 3billion Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564

Talk to a Data Expert

Have a question? We'll get back to you promptly.